Novo Nordisk vs AstraZeneca: Revenue Comparison
Novo Nordisk (NVO) and AstraZeneca (AZN) are peers in GLP-1. Novo Nordisk reported revenue of $96.8B as of Q1 2026, compared with $15.3B for AstraZeneca. Novo Nordisk leads on revenue.
Novo Nordisk's gross margin is 86.0% versus 82.5% for AstraZeneca. Novo Nordisk's net margin is 50.1% versus 20.1% for AstraZeneca.
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q1 2026: Novo Nordisk 96.823, AstraZeneca 15.288.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Novo Nordisk, AstraZeneca.| Metric | Novo Nordisk | AstraZeneca |
|---|---|---|
| Market Cap | - | - |
| Revenue | $96.82B | $15.29B |
| Cost of Revenue | $13.60B | $2.68B |
| Gross Profit | $83.22B | $12.61B |
| Operating Income | $59.62B | $4.25B |
| Net Income | $48.56B | $3.08B |
| R&D Expense | $10.28B | $3.49B |
| Earnings Per Share | $10.91 | $3.94 |
| Gross Margin | 86.0% | 82.5% |
| Operating Margin | 61.6% | 27.8% |
| Net Profit Margin | 50.1% | 20.1% |
| Free Cash Flow | $12.04B | $1.82B |
| Cumulative Free Cash Flow | $654.97B | $119.09B |
| Operating Cash Flow | $24.08B | $3.36B |
| Cash & Equivalents | $21.13B | $7.56B |